[Federal Register Volume 72, Number 103 (Wednesday, May 30, 2007)]
[Notices]
[Pages 30017-30018]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-10332]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

A Fullerene-Based Anticoagulant

    Description of Technology: This technology relates to the use of 
substituted or modified C60 fullerenes, which are carbon-
based molecular cages that resemble soccer balls, for the prevention or 
treatment of thrombosis, peripheral arterial occlusion, and catheter 
obstruction. Described are compositions and methods for administering 
such compounds at the implantation site of an in-dwelling device and 
methods of coating in-dwelling devices with such compounds. Such 
devices include stents, stent grafts, pacemakers, defibrillators, 
venous valves, heart valves, sutures, catheters, and drug delivery 
ports.
    Applications: Non-invasive method of preventing clot formation.
    Market: Anticoagulation therapy averages several billion dollars a 
year.
    Further Research Required: Anti-coagulant properties of C-60 
derivatives in vivo; Device coating and in vivo efficacy; Safety 
evaluation of device, in vivo models.
    Inventors: Marina Dobrovolskaia et al. (NCI)
    Patent Status: PCT Application No. PCT/US2006/041838 filed 25 Oct 
2006 (HHS Reference No. E-140-2006/0 PCT-01)
    Licensing Status: Available for licensing.
    Licensing Contact: Fatima Sayyid, M.H.P.M.; 301/435-4521; 
[email protected]

Aminoalkyl Substituted O\6\-Benzylguanine Derivatives as Inactivators 
of O\6\-Alkylguanine-DNA Alkyltransferase and Adjuvants for 
Chemotherapy

    Description of Technology: This present invention describes novel 
class of compounds that inactivate the DNA repair protein O\6\-
alkylguanine-DNA alkyltransferase (AGT). Inactivation of this protein 
improves therapeutic effectiveness of chemotherapy drugs that modify 
O\6\-position of DNA guanine residues.
    These new compounds have several advantages over the existing O\6\-
benzylguanine compounds in terms of being more water soluble, being 
more potent, and the compounds are more readily formulated in water or 
phosphate buffered saline solutions than O\6\-benzylguanine compounds.
    The existing O\6\-benzylguanine compounds are currently in Phase II 
and III clinical trials. The new aminoalkyl substituted O\6\-
benzylguanine derivatives are currently in preclinical trials.
    Applications and Modality: New compounds have potential to improve 
chemotherapy treatment with anticancer agents; New compounds are more 
water soluble, more readily formulated and more potent than existing 
O\6\-benzylguanine compounds.
    Market: 600,000 deaths from cancer related diseases were estimated 
in 2006; In 2006, cancer drug sales were estimated to be $25 billion.

[[Page 30018]]

    Development Status: The technology is currently in the pre-clinical 
stage of development.
    Inventors: Robert C. Moschel (NCI) et al.
    Relevant Publication: A manuscript directly related to the above 
technology will be available as soon as it is accepted for publication.
    Patent Status: U.S. Patent Application No. 11/683,310 filed 07 Mar 
2007 (HHS Reference No. E-307-2004/1-US-01).
    Licensing Status: Available for exclusive and non-exclusive 
licensing.
    Licensing Contact: Adaku Nwachukwu, J.D.; 301/435-5560; 
[email protected].

Inhibition of ABC Transporters by Transmembrane Domain Analogs

    Description of Technology: ABC transporters contain multiple 
transmembrane domains and are involved in the translocation of a 
variety of substrates across cell membranes. Upregulation of these 
transporters contributes to multiple drug resistance in cancer 
chemotherapy wherein these transporters export chemotherapeutic agents 
out of cancer cells. The inventors have found that P-glycoprotein and 
ABCG2 transporter can be effectively inhibited by properly modified 
peptides corresponding to certain transmembrane domains. This 
inhibition can be used to overcome drug resistance in resistant tumors.
    Applications: Therapeutics that enhance cancer treatments.
    Market: Cancer is the second leading cause of death in the United 
States; 600,000 deaths caused by cancer in 2006; Worldwide incidence of 
new cancer patients is forecast to increase from 4.2 million cases in 
the major cancer markets in 2005 to 4.6 million in 2010; Global 
anticancer market was worth over $42 billion in 2005 and by 2010, the 
global cancer market is expected to generate sales in excess of $60 
billion.
    Development Status: The technology is currently in the pre-clinical 
stage of development.
    Inventors: Nadya I. Tarasova et al. (NCI)
    Publications:
    1. NI Tarasova et al. Transmembrane inhibitors of P-glycoprotein, 
an ABC transporter. J Med Chem. 2005 Jun 2;48(11):3768-3775.
    2. NI Tarasova et al. Inhibition of G-protein-coupled receptor 
function by disruption of transmembrane domain interactions. J Biol 
Chem. 1999 Dec 3;274(49):34911-34915.
    Patent Status: U.S. Patent Application No. 10/130,192 filed 13 May 
2002 (HHS Reference No. E-019-2000/2-US-02); PCT Patent Application No. 
PCT/US2000/31817 filed 17 Nov 2000 (HHS Reference No. E-019-2000/2-PCT-
01); U.S. Provisional Patent Application No. 60/166,767 filed 22 Nov 
1999 (HHS Reference No. E-019-2000/1-US-01); U.S. Provisional Patent 
Application No. 60/166,382 filed 18 Nov 1999 (HHS Reference No. E-019-
2000/0-US-01).
    Licensing Status: Available for exclusive or non-exclusive 
licensing.
    Licensing Contact: Jennifer Wong; 301/435-4633; 
[email protected].
    Collaborative Research Opportunity: The National Cancer Institute's 
Structural Biophysics Laboratory is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize inhibitors of multiple drug 
resistance proteins. Please contact John D. Hewes, Ph.D. at 301-435-
3121 or [email protected] for more information.

    Dated: May 21, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E7-10332 Filed 5-29-07; 8:45 am]
BILLING CODE 4140-01-P